Sector policy

-
Sector policy
Sector policy: Promote foreign investment projects in Cuba, both for the construction of new manufacturing facilities for final forms of generic drugs, and for the development and manufacture of biotechnological, novel and biosimilar products primarily for export.
-
Sector information
The Group of Biotechnology and Pharmaceutical Industries, BioCubaFarma, produces medicines, equipment and high technology services, based on the scientific-technical development of the country aimed at improving the health of the Cuban people and the generation of exportable goods and services, as well as advanced technologies in food production. Among its main productions are prophylactic vaccines against infectious diseases, biopharmaceuticals for the treatment of cancer (includes monoclonal antibodies and therapeutic vaccines), products for the prevention and treatment of cardiovascular diseases, as well as for the treatment of Diabetic Foot Ulcer. New generation generic products and pharmaceutical compounds are also manufactured, as well as systems for the early diagnosis and prevention of malignant tumors, malformations, heredometabolic diseases and others. Similarly, products are offered from natural and traditional medicine, as well as human placenta, blood products and agricultural research and advanced technology, nanotechnology, neuroscience and neurotechnology medical equipment. The high scientific level of human resources in the Cuban biopharmaceutical industry guarantees the quality and competitiveness of its projects. Likewise, it promotes direct foreign investment in Cuba, fundamentally within the Mariel Special Development Zone. The latter is contributing significantly to the growth of the sector through its regulatory framework, favorable for those companies that wish to invest in research facilities.
PROJECTS BY PROVINCES
Business Oportunity

Production of aloe vera gel in Mayabeque province
Sector: Pharmaceutical and biotechnology industry.
3.5 million USD.
Creation of human plasma fractionation and purification facility
Sector: Pharmaceutical and biotechnology industry.
12.0 million USD.

Plant for the production of products derived from human placenta.
Sector: Pharmaceutical and biotechnology industry.
14.8 million USD.

Oral solids plant (tablets, capsules and antiretrovirals)
Sector: Pharmaceutical and biotechnology industry.
150.0 million USD.

Joint Venture Company to manufacture semi-solid medicines
Sector: Pharmaceutical and biotechnology industry.
15.0 million USD.

Manufacture of recombinant protein production,obtained by cultivating mammalian cells on an industrial scale
Sector: Pharmaceutical and biotechnology industry.
80.2 million USD.